Hamilton company BioVittoria says it is in discussions with potential strategic partners and private investors in both China and the US.It also expects full Food and Drug Administration (FDA) approval through the GRAS (generally recognised as safe) status
Andrea Deuchrass Thu, 28 Jan 2010
Hamilton company BioVittoria says it is in discussions with potential strategic partners and private investors in both China and the US.
It also expects full Food and Drug Administration (FDA) approval through the GRAS (generally recognised as safe) status by the end of January or February.
The
Want to read more? It's easy.
Choose your best value subscription option
Student
Exclusive offer for uni students studying at a New Zealand university (valued at $499).
